title: Antitumour activity of Lycium chinensis polysaccharides in liver cancer rats.
abstract: In the present study, polysaccharides were extracted from the Lycium chinensis (LCP). Rats were divided into four groups. Two groups (Groups A) were maintained on the basal diet, whereas the remaining three groups (Groups B, C and D) had free access to the basal diet and were orally fed with LCP at 200 mg/kg b.w. for Group B, 400 mg/kg b.w. for Group C and 600 mg/kg b.w. for Group D, respectively. Following 4 weeks of this dietary regimen, hepatocarcinogenesis was initiated in all animals by a single intraperitoneal DENA (Sigma-Aldrich, St. Louis, MO, USA) injection at a dose of 200 mg/kg body weight (mixed with peanut oil). Results still showed that L. chinensis polysaccharides (LCP) increased spleen, thymus indexs, antioxidant enzymes activities and decreased oxidative injury. In addition, LCP still significantly affect VEGF and Cyclin D1 proteins expression in liver cancer rats. It can be concluded that LCP exhibited remarkable protective effects against diethylnitrosamine (DEN)-induced oxidative hepatic injury in liver cancer rats.
authors.affiliation: Department of Hepatobiliary Oncology, Cancer Center, Sun Yat-sen University, 651 Dongfeng East Road, Guangzhou 510060, Guangdong Province, China.
authors.forename: BoKang
authors.initials: B
authors.lastname: Cui
authors.forename: YanFeng
authors.initials: Y
authors.lastname: Chen
authors.forename: Su
authors.initials: S
authors.lastname: Liu
authors.forename: Jun
authors.initials: J
authors.lastname: Wang
authors.forename: ShuHong
authors.initials: S
authors.lastname: Li
authors.forename: QiBo
authors.initials: Q
authors.lastname: Wang
authors.forename: ShengPing
authors.initials: S
authors.lastname: Li
authors.forename: MinShan
authors.initials: M
authors.lastname: Chen
authors.forename: XiaoJun
authors.initials: X
authors.lastname: Lin
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D019938:Cyclin D1 / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008114:Liver Neoplasms, Experimental / Q000378:metabolism*; D032305:Lycium / Q000737:chemistry*; D011134:Polysaccharides / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013154:Spleen / Q000187:drug effects / Q000378:metabolism; D013950:Thymus Gland / Q000187:drug effects / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D011134:Polysaccharides; D042461:Vascular Endothelial Growth Factor A; D019938:Cyclin D1